Selection bias in clinical trials

Breast Disease

Volumn 14, Issue , 2001, Pages 31-40

  Miller, K D ^a   Rahman, Z U ^a   Sledge G W , Jr ^a  

^a Indiana Cancer Pavilion   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ANALYSIS; ARTICLE; BREAST CANCER; CHEMOTHERAPY; CLINICAL RESEARCH; CONTROL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG MEGADOSE; DRUG RESEARCH; HUMAN; MIGRATION; OBSERVER VARIATION; PRIORITY JOURNAL; REVIEW;

EID: 0035670908     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2001-14105     Document Type: Article

References (45)

1. Bias
2. Bias in analytic research
3. Classification, direction, and prevention of bias in epidemiologic research
4. Controlled studies in clinical cancer research
5. Non-randomized controls in cancer clinical trials
6. A comparison of observational studies and randomized, controlled studies
7. Randomized, controlled trials, observational studies, and the hierarchy of research designs
8. Randomized trials or observational tribulations?
9. Randomized versus historical controls for clinical trials
10. A comparison of randomized concurrent control groups with matched historical control groups: Are historical controls valid?
11. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities
12. Adjuvant chemotherapy in the treatment of primary soft tissue sarcomas: A preliminary report
13. Treatment of testicular cancer: A new and improved model
14. The use of historical controls in breast cancer. An assessment in three consecutive trials
15. The Will Rogers Phenomenon: Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer
16. Impact of active and passive exclusions on the results of a clinical trial in multiple myeloma
17. Selection bias, survival, and brachytherapy for glioma
18. Subgroup analysis and other (mis)uses of baseline data in clinical trials
19. Menstrual influence on surgical cure of breast cancer
20. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer
21. Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival
22. Timing of surgery for breast cancer and menstrual cycle
23. Menstrual effect on surgical cure of breast cancer
24. Menstrual effect on surgical cure of breast cancer
25. Timing of surgery in breast cancer
26. Optimal mastectomy timing
27. Selection bias in clinical trials
28. Physician-determined patient risk of toxic effects: Impact of enrollment and decision making in phase I cancer trials
29. Bias in treatment assignment in controlled clinical trials
30. Cancer statistics, 1999
31. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
32. Treatment of breast cancer
33. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America
34. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy
35. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma
36. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer
37. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast CALBG9082/SWOG9114/NCIC MA-13
38. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes
39. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and ten or more positive axillary lymph nodes
40. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer
41. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer
42. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer
43. Patient selection in high-dose chemotherapy trials: Relevance in high-risk breast cancer
44. Randomized phase III study of high-dose chemotherapy with cyclo-phosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes